Retinitis Pigmentosa – Epidemiology – Mature Markets Data
Clarivate’s Epidemiology’s coverage of RP comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the diagnosed prevalence of RP for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan in this report.
Clarivate’s Epidemiology’s RP forecast will answer the following questions:
- Of all people diagnosed with RP, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RP over the forecast period?
All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate’s Epidemiology provides at least ten years of forecast data for the following RP patient populations:
- Diagnosed Prevalent Cases of Inherited Retinal Dystrophy
- Diagnosed Prevalent Cases of RetinitisPigmentosa
- Drug-Treated Prevalent Cases of RetinitisPigmentosa
- Clinical Subtypes of RetinitisPigmentosa
- Diagnosed Prevalent Cases of Usher Syndrome
- Diagnosed Prevalent Cases of Bardet-Biedl Syndrome
- Diagnosed Prevalent Cases with RPE65Mutation
- Diagnosed Prevalent Cases of Leber’s Congenital Amaurosis
- Diagnosed Prevalent Cases of Choroideremia
Note: coverage may vary by country and region.
Table of contents
- Retinitis Pigmentosa - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Diagnosed Prevalence of Retinitis Pigmentosa per 100,000 People of All Ages in 2021 and 2041
- Diagnosed Prevalence of Retinitis Pigmentosa per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Retinitis Pigmentosa over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Retinitis Pigmentosa over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases by Drug-Treated Status
- Analysis of Diagnosed Prevalent Cases by Drug-Treated Status
- Analysis of Diagnosed Prevalent Cases of non-syndromic Retinitis Pigmentosa by Inheritance Pattern
- Analysis of Diagnosed Prevalent Cases of non-syndromic Retinitis Pigmentosa by Inheritance Pattern
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases of Inherited Retinal Dystrophy
- Diagnosed Prevalent Cases of Retinitis Pigmentosa
- Drug-Treated Prevalent Cases of Retinitis Pigmentosa
- Diagnosed Prevalent Cases of Retinitis Pigmentosa by Clinical Subtype
- Diagnosed Prevalent Cases of Usher Syndrome
- Diagnosed Prevalent Cases of Bardet-Biedl Syndrome
- Diagnosed Prevalent Cases of RPE65-Associated Retinitis Pigmentosa
- Drug-Treatable Prevalent Cases of RPE65-Associated Retinitis Pigmentosa
- Diagnosed Prevalent Cases of X-Linked Retinitis Pigmentosa
- Diagnosed Prevalent Cases of Leber Congenital Amaurosis
- Diagnosed Prevalent Cases of RPE65-Associated Leber Congenital Amaurosis
- Drug-Treatable Prevalent Cases of RPE65-Associated Leber Congenital Amaurosis
- Diagnosed Prevalent Cases of Choroideremia
- Drug-Treatable Prevalent Cases of Choroideremia
- Reference Materials
- Introduction
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.